Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa epar ema

besponsa epar ema

Перейти к контенту

Главное меню:

besponsa epar ema
Besponsa - European Medicines Agency - ema.europa.eu, Assessment report - ema.europa.eu, EMA Issues Positive Opinions for Four Cancer Drugs in , Besponsa: Is this really a viable new treatment for ALL , Besponsa: Uses, Side Effects, Benefits/Risks | Drugs.com, EMA Recommends Granting a Marketing Authorisation for , European Medicines Agency - Find medicine, European Medicines Agency - Find medicine - Gardasil, Besponsa | myHealthbox.
6o](-//[Nt1{W\|:Ha%5I]K?NX{U=VTMDgo8XDLF@g rzbϾFeA%!QX공:a-4Fb0d78E1׷Ug[%IURF:ڵ>`vhQ6[UA5p8.'hʭwE%0VH7e۬>Zdz6 [*2*G]@*Pʘۃ8ؾ3NQT ڂLت*-ĖTUg]w%Bej3ԷN;4D(N|p"eanO_OuuH8q9 M3yNoz\F."Bg=Y*ǫJmrzUYEټ1?e.*a5q-J`h渙6De2 EX%vxRXhlL;oT}8Qa~pCzjgV>ط}/|O$Hg렵sIN6fP&bئPq&nb;9tXςUt7m],+~(K#K#V`ˤтD2'Ev3mWR]EG"Օv }>3q t}DickR9wN9iƧl*v\qJ)q\ˑ>ކ|latt]iZC=&F):Z/[Y5"~J4(RL9؊ߚD3NK|HJ+qG#'$cue=UTNa.1LCǮ'ӟK|ą%. Besponsa is used on its own in adults whose cancer has come back or did not respond to previous treatment. Besponsa is only used in patients with ‘CD22-positive B-cell precursor ALL’. This means that patients’ have a particular protein (CD22) on the surface of their white blood cells. In patients who have a type of chromosome known as Philadelphia-chromosome, treatment with a cancer medicine called a tyrosine kinase inhibitor should have been tried before starting Besponsa.. European Medicines Agency (EMA) for BESPONSA, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was.
The EMA adopted a positive opinion recommending approval of the anti-CD22 antibody inotuzumab ozogamicin (BESPONSA ®, Pfizer Limited) for use as monotherapy for treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia-chromosome positive (Ph+) ALL should have received treatment with at least one prior tyrosine kinase inhibitor (TKI). The recommendation for approval is based on results from the. August 18, 2017 – B-cell precursor acute lymphoblastic leukemia is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.. For more information about treatment with Besponsa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.. The active substance of Besponsa is inotuzumab ozogamicin, a humanised immunoglobulin class G subtype 4 (IgG4) antibody (ATC code: L01XC26) that specifically recognises human CD22. Besponsa has been shown to increase the proportion of patients who have complete remission and molecular remission and to delay the progression of disease.. The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level.. Three studies of Gardasil given as three doses looked at the ability of Gardasil to prevent infection with HPV types 6, 11, 16 and 18 and genital warts caused by these HPV types in almost 4,000 women aged between 24 and 45 years, and at the development of antibodies against these HPV types in around 1,700 girls and boys aged between nine and 15 years..
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню